2025 Q4 -tulosraportti
Vain PDF
68 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 20 | - | - | ||
| 35 | - | - | ||
| 9 | - | - | ||
| 1 | - | - | ||
| 67 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 42 569 | 42 569 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 42 569 | 42 569 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.4. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 7.11.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 21.5.2025 | ||
2024 Q4 -tulosraportti 14.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·31.3.Genovis: The waiting time is over – Now the scaling begins.. After a couple of weeks with exciting movements, it's time to look at the fundamental case in Genovis again. We have talked about the potential for a long time, but if we look at the latest announcements (incl. the new partnership with Single Cell Discoveries and the license agreement for EndoS2), the signal is clear: The research and development phase has been completed. Why is this a turning point? The enzymes are world-class: We are no longer talking about "hope". Their enzymes are the de facto standard in the industry when global giants need to analyze and develop the medicine of the future (ADCs and complex antibodies). No one touches the quality. From R&D to commercial machine: The heavy investment phase in development is behind us. Now it's about scaling. Once the products are developed, the costs of producing them are minimal compared to the sales price. Margins in a class of their own: This is where the case becomes really fun for us shareholders. Genovis operates with gross margins that most other companies can only dream of. Every extra krone in growth almost goes directly to the bottom line now that the machinery is well-oiled. This is not a buy/sell recommendation. Do your own analysis of this exciting company..
·31.3.How big a breakthrough is this? It should surely save some money?
25.3.25.3.Geno is back!!!·26.3.It will be exciting to see how this can develop. It's positive that they didn't get exclusive rights either.- ·12.2.Anyone who wants to share their thoughts on today's report? Sector peer Arcticzymes reported today and seems to be rewarded for similar figures.
·12.2.The report was probably fine compared to the same quarter the year before. But sometimes it's also a question of what investors expect, and perhaps it's not going fast enough. Underlying, there is growth in the core business, and it's also mentioned in the report that it's super positive due to the sale of the antibody business, that for the year they reach roughly the same regenue-level. That being said, the cynical one would probably argue that it's a relatively flat development. On top of that, with increased personnel costs. The optimistic one would argue that a lot is happening and that it's still an incredible gross margin, which makes it super attractive. However, no one can say much about the trend. There's a long way up to the 80 SEK it once stood at. I will, however, continue to hold mine (have low GAK). I'm mostly in the optimist boat, but I'm probably a bit worried about whether they can show what the market expects fast enough, because the stock is simply punished for only living up to expectations and never exceeding them.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
68 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·31.3.Genovis: The waiting time is over – Now the scaling begins.. After a couple of weeks with exciting movements, it's time to look at the fundamental case in Genovis again. We have talked about the potential for a long time, but if we look at the latest announcements (incl. the new partnership with Single Cell Discoveries and the license agreement for EndoS2), the signal is clear: The research and development phase has been completed. Why is this a turning point? The enzymes are world-class: We are no longer talking about "hope". Their enzymes are the de facto standard in the industry when global giants need to analyze and develop the medicine of the future (ADCs and complex antibodies). No one touches the quality. From R&D to commercial machine: The heavy investment phase in development is behind us. Now it's about scaling. Once the products are developed, the costs of producing them are minimal compared to the sales price. Margins in a class of their own: This is where the case becomes really fun for us shareholders. Genovis operates with gross margins that most other companies can only dream of. Every extra krone in growth almost goes directly to the bottom line now that the machinery is well-oiled. This is not a buy/sell recommendation. Do your own analysis of this exciting company..
- ·31.3.How big a breakthrough is this? It should surely save some money?
- 25.3.25.3.Geno is back!!!·26.3.It will be exciting to see how this can develop. It's positive that they didn't get exclusive rights either.
- ·12.2.Anyone who wants to share their thoughts on today's report? Sector peer Arcticzymes reported today and seems to be rewarded for similar figures.·12.2.The report was probably fine compared to the same quarter the year before. But sometimes it's also a question of what investors expect, and perhaps it's not going fast enough. Underlying, there is growth in the core business, and it's also mentioned in the report that it's super positive due to the sale of the antibody business, that for the year they reach roughly the same regenue-level. That being said, the cynical one would probably argue that it's a relatively flat development. On top of that, with increased personnel costs. The optimistic one would argue that a lot is happening and that it's still an incredible gross margin, which makes it super attractive. However, no one can say much about the trend. There's a long way up to the 80 SEK it once stood at. I will, however, continue to hold mine (have low GAK). I'm mostly in the optimist boat, but I'm probably a bit worried about whether they can show what the market expects fast enough, because the stock is simply punished for only living up to expectations and never exceeding them.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 20 | - | - | ||
| 35 | - | - | ||
| 9 | - | - | ||
| 1 | - | - | ||
| 67 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 42 569 | 42 569 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 42 569 | 42 569 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.4. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 7.11.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 21.5.2025 | ||
2024 Q4 -tulosraportti 14.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
68 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.4. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 7.11.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 21.5.2025 | ||
2024 Q4 -tulosraportti 14.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·31.3.Genovis: The waiting time is over – Now the scaling begins.. After a couple of weeks with exciting movements, it's time to look at the fundamental case in Genovis again. We have talked about the potential for a long time, but if we look at the latest announcements (incl. the new partnership with Single Cell Discoveries and the license agreement for EndoS2), the signal is clear: The research and development phase has been completed. Why is this a turning point? The enzymes are world-class: We are no longer talking about "hope". Their enzymes are the de facto standard in the industry when global giants need to analyze and develop the medicine of the future (ADCs and complex antibodies). No one touches the quality. From R&D to commercial machine: The heavy investment phase in development is behind us. Now it's about scaling. Once the products are developed, the costs of producing them are minimal compared to the sales price. Margins in a class of their own: This is where the case becomes really fun for us shareholders. Genovis operates with gross margins that most other companies can only dream of. Every extra krone in growth almost goes directly to the bottom line now that the machinery is well-oiled. This is not a buy/sell recommendation. Do your own analysis of this exciting company..
- ·31.3.How big a breakthrough is this? It should surely save some money?
- 25.3.25.3.Geno is back!!!·26.3.It will be exciting to see how this can develop. It's positive that they didn't get exclusive rights either.
- ·12.2.Anyone who wants to share their thoughts on today's report? Sector peer Arcticzymes reported today and seems to be rewarded for similar figures.·12.2.The report was probably fine compared to the same quarter the year before. But sometimes it's also a question of what investors expect, and perhaps it's not going fast enough. Underlying, there is growth in the core business, and it's also mentioned in the report that it's super positive due to the sale of the antibody business, that for the year they reach roughly the same regenue-level. That being said, the cynical one would probably argue that it's a relatively flat development. On top of that, with increased personnel costs. The optimistic one would argue that a lot is happening and that it's still an incredible gross margin, which makes it super attractive. However, no one can say much about the trend. There's a long way up to the 80 SEK it once stood at. I will, however, continue to hold mine (have low GAK). I'm mostly in the optimist boat, but I'm probably a bit worried about whether they can show what the market expects fast enough, because the stock is simply punished for only living up to expectations and never exceeding them.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 20 | - | - | ||
| 35 | - | - | ||
| 9 | - | - | ||
| 1 | - | - | ||
| 67 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 42 569 | 42 569 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 42 569 | 42 569 | 0 | 0 |